Device companies are getting a first chance to participate in CDRH’s innovation pathway pilot focused on early, hyper-collaboration between sponsors and reviewers under a new stage of the program announced April 9.
FDA has selected three investigational-stage devices for end-stage renal disease as part of its innovation pathway 2.0 program.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?